Economic data collection during efficacy trials will be discussed at HHS workshop.
Executive Summary
ECONOMIC DATA COLLECTION IN CONJUNCTION WITH EFFICACY TRIALS TO BE DISCUSSED at the Department of Health & Human Services cost-effectiveness workshop scheduled for Nov. 25-26 at the National Institutes of Health campus in Bethesda, Md. The workshop is organized around the Panel on Cost-Effectiveness in Health and Medicine report released earlier this year ("The Pink Sheet" Aug. 5, T&G-16). The report states that a "rigorously designed clinical trial" may be necessary for a cost-effectiveness analysis of "a pharmaceutical agent with the potential to create undesired side effects and for which small statistical biases in study data can lead to misleading results."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth